Approved for 6 indications
Treatment
of PE
Reduction in risk
of stroke/systemic
embolism in NVAF
Prophylaxis of DVT, which
may lead to PE, after hip
replacement surgery
Treatment
of DVT
Reduction in the
risk of recurrent
DVT and PE
following initial
therapy
Prophylaxis of DVT, which
may lead to PE, after knee
replacement surgery
NVAF=nonvalvular atrial fibrillation; DVT=deep vein thrombosis; PE=pulmonary embolism.
SELECTED IMPORTANT SAFETY INFORMATION
WARNING: (A) PREMATURE DISCONTINUATION OF ELIQUIS INCREASES THE RISK OF THROMBOTIC EVENTS,
(B) SPINAL/EPIDURAL HEMATOMA
(A) Premature discontinuation of any oral anticoagulant, including ELIQUIS, increases the risk of thrombotic events. If
anticoagulation with ELIQUIS is discontinued for a reason other than pathological bleeding or completion of a course of therapy,
consider coverage with another anticoagulant.
(B) Epidural or spinal hematomas may occur in patients treated with ELIQUIS who are receiving neuraxial anesthesia or undergoing
spinal puncture. These hematomas may result in long-term or permanent paralysis. Consider these risks when scheduling patients
for spinal procedures. Factors that can increase the risk of developing epidural or spinal hematomas in these patients include:
• use of indwelling epidural catheters
• concomitant use of other drugs that affect hemostasis, such as nonsteroidal anti-inflammatory drugs (NSAIDs), platelet inhibitors,
other anticoagulants
• a history of traumatic or repeated epidural or spinal punctures
• a history of spinal deformity or spinal surgery
• optimal timing between the administration of ELIQUIS and neuraxial procedures is not known
Monitor patients frequently for signs and symptoms of neurological impairment. If neurological compromise is noted, urgent
treatment is necessary.
Consider the benefits and risks before neuraxial intervention in pat